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Abstract
Background: A major challenge in oncology is the selection of the most effective chemotherapeutic agents for individual
patients, while the administration of ineffective chemotherapy increases mortality and decreases quality of life in cancer
patients. This emphasizes the need to evaluate every patient’s probability of responding to each chemotherapeutic agent
and limiting the agents used to those most likely to be effective.
Methods and Results: Using gene expression data on the NCI-60 and corresponding drug sensitivity, mRNA and microRNA
profiles were developed representing sensitivity to individual chemotherapeutic agents. The mRNA signatures were tested
in an independent cohort of 133 breast cancer patients treated with the TFAC (paclitaxel, 5-fluorouracil, adriamycin, and
cyclophosphamide) chemotherapy regimen. To further dissect the biology of resistance, we applied signatures of oncogenic
pathway activation and performed hierarchical clustering. We then used mRNA signatures of chemotherapy sensitivity to
identify alternative therapeutics for patients resistant to TFAC. Profiles from mRNA and microRNA expression data represent
distinct biologic mechanisms of resistance to common cytotoxic agents. The individual mRNA signatures were validated in
an independent dataset of breast tumors (P=0.002, NPV=82%). When the accuracy of the signatures was analyzed based
on molecular variables, the predictive ability was found to be greater in basal-like than non basal-like patients (P=0.03 and
P=0.06). Samples from patients with co-activated Myc and E2F represented the cohort with the lowest percentage (8%) of
responders. Using mRNA signatures of sensitivity to other cytotoxic agents, we predict that TFAC non-responders are more
likely to be sensitive to docetaxel (P=0.04), representing a viable alternative therapy.
Conclusions: Our results suggest that the optimal strategy for chemotherapy sensitivity prediction integrates molecular
variables such as ER and HER2 status with corresponding microRNA and mRNA expression profiles. Importantly, we also
present evidence to support the concept that analysis of molecular variables can present a rational strategy to identifying
alternative therapeutic opportunities.
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Introduction
One of the major challenges facing the field of oncology is the
selection of the most effective chemotherapy agents for individual
patients. While steps have been taken towards using biomarkers to
select patients eligible to receive certain targeted therapies,
selection of the more common cytotoxic agents remains largely
arbitrary [1]. For example, patients with breast cancer may be
given the ‘‘TFAC’’ (paclitaxel (T), 5-fluorouracil (F), adriamycin
(A), and cyclophosphamide(C)) treatment regimen, DC (docetaxel
and cyclophosphamide) treatment, or AC (adriamycin and
cyclophosphamide) treatment in the neo-adjuvant setting, with
little guidance as to which will actually be most effective for their
particular disease. Furthermore, the administration of ineffective
chemotherapy agents increases the probability of side effects and
decreases the quality of life of many cancer patients[2,3], which
further emphasizes the need to develop strategies that evaluate
each individual patient’s probability of responding to commonly
used chemotherapeutic agents and limiting the agents used to
those most likely to be effective. Recent advances in our
understanding of cancer biology have offered a potential approach
to meeting this challenge by using gene expression signatures of
sensitive or resistant cell lines to predict patient response to a panel
of commonly used chemotherapy agents [4,5,6,7]. These initial
gene signatures, however, were created using U95 Av2 Affymetrix
gene array chips, while in recent months the volume of usable data
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1908has shifted to include the more comprehensive U133 gene
expression platform. Thus, U133A expression data from the
NCI-60 panel of cell lines, chosen using identical approaches as
previously described[4], was used to develop robust, refined gene
expression signatures of chemosensitivity. Using an independent
dataset (n=133) of breast cancer tumor samples from patients
treated neoadjuvantly with combination (TFAC) chemotherapy,
we validated the performance of the individual predictors of
sensitivity to paclitaxel (T), 5-fluorouracil (F), adriamycin (A), and
cyclophosphamide (C), as well as a combined predictor of TFAC
sensitivity. We also use microRNA data from the NCI-60 cell lines
to develop microRNA gene expression profiles of chemosensitivity,
in an attempt to understand the biologic interplay between
relevant microRNA expression in conjunction with the corre-
sponding messenger RNA data, which could potentially refine the
predictive ability of gene signatures. Finally, we use signatures of
deregulated oncogenic signaling pathways in breast tumors to
develop a strategy that identifies opportunities for other novel
therapeutic drugs in patients resistant to chemotherapy, using the
cohort of patients treated with TFAC as an example.
Results
mRNA signatures of paclitaxel, 5-fluorouracil, adriamycin,
and cyclophosphamide sensitivity
Using identical cell lines identified previously as representing the
extremes of sensitivity, gene signatures representative of sensitivity
to paclitaxel, 5-fluorouracil, adriamycin, and cyclophosphamide
were developed. The leave-one-out cross-validation probabilities
for each chemotherapy sensitivity signature showed separation of
sensitive and resistant cell lines with an accuracy always exceeding
95% (Figure S1). The heatmaps (Fig 1a) of the probability values
of the top genes used for prediction showed a clear demarcation
between sensitive and resistant cell lines and the genes that were
upregulated or downregulated in each.
The gene ontology of the genes used in each predictor, as
discovered by performing a Batch Query on the Affymetrix
website (www.affymetrix.com), included a plethora of genes and
pathways thought to be important in cancer pharmacology and
biology (Table S1). Genes used in predictors included those key in
cell cycle regulation, signal recognition, tumor necrosis factor
pathways, and growth arrest. Of note, the paclitaxel sensitivity
signature included the Jun proto-oncogene, while the adriamycin
signature included multiple members of the Ras-associated
domain family as well as the epidermal growth factor receptor
(EGFR) gene. The 5-fluorouracil signature included genes for
transcription regulation and a cyclin-dependent kinase inhibitor
(CDKN2A) thought to play a role in cancer progression, while the
cyclophosphamide signature included genes (e.g. SET) commonly
involved in leukemogenesis. Together, the ontology of the genes
that constitute the four signatures reaffirms our confidence in their
predictive ability.
MicroRNA profiles characterize biology underlying
chemotherapeutic resistance
As a further step to advance our understanding of gene
expression phenotypes of chemotherapeutic sensitivity and to
begin to understand the role of microRNAs in predicting
chemosensitivity, we also made use of relevant microRNA data
from the individual NCI-60 cell lines. The heatmaps representing
the microRNA chemosensitivity profiles showed demarcations
between chemosensitive and resistant cell lines similar to the
mRNA predictors (Figure 1b). Of particular interest is the fact that
many of the individual microRNAs implicated in the individual
profiles of chemosensitivity have previously been shown to have
altered expression in human tumors (Table S2). Interestingly,
miR-34, which was recently reported to mimic TP53 activi-
ty[8,9,10,11,12], was downregulated in the sensitive cell lines in
the 5-fluorouracil and paclitaxel microRNA signatures, indicating
a possible connection between chemosensitivity to those drugs and
the well-known TP53 tumor suppressor network. The fact that
miR-34 was downregulated in cell lines sensitive to paclitaxel was
surprising, as mutations in the TP53 pathway are thought to
Figure 1. mRNA (a) and miRNA (b) gene signatures of sensitivity to paclitaxel, 5-fluorouracil, adriamycin, and cyclophosphamide.
Gene number is displayed on the vertical axes, while sample number is listed horizontally.
doi:10.1371/journal.pone.0001908.g001
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the inhibitory pathways of TP53 include abnormal tubulin
detection and subsequent cell cycle arrest, miR-34 follows a
separate path toward tumor suppression. In addition, miR-17 was
downregulated in cell lines sensitive to adriamycin and cyclophos-
phamide, drugs commonly used in the treatment of lymphopro-
liferative disorders. The downregulation of miR-17 may represent
an explanation for the effectiveness of these drugs in specific
hematologic malignancies that are dependent on Myc pathway
deregulation for their pathogenesis (e.g. chronic lymphocytic
leukemia and aggressive lymphomas), since miR-17 functions
synergistically with Myc to promote aggressive tumor growth in
lymphoma[14]. Another microRNA thought to be involved with
the Myc pathway, let-7, was implicated in the cyclophosphamide
sensitivity signature in our analysis. Further, miR-let-7a, which has
been shown to repress expression of the Myc transcription
factor[15], was found to be downregulated in the cell lines
sensitive to cyclophosphamide, an alkylating agent. These findings
would imply that, if let-7 is downregulated in sensitive cell lines,
Myc is upregulated, but the resultant proliferation is tempered by
the repressive action of cyclophosphamide on cell replication.
Lastly, miR-200b, which when inhibited confers sensitivity to
chemotherapy in malignant cholangiocytes[16], was also found in
our signature to be downregulated in cells sensitive to adriamycin,
the current standard of care in the treatment for hepatobiliary
tumors. MiR-200b suppresses a tumor suppressor gene (PTPN12)
which is thought to inactivate the common oncogenes Src and
Ras[16], such that the downregulation of miR-200b in sensitive
cell lines allows the resultant proliferating cells to be targeted by
adriamycin, a Topoisomerase II inhibitor. These findings suggest
that, when utilized in an integrated approach, microRNA
expression profiles in conjunction with corresponding gene
expression data may provide a critical link for understanding
mechanisms involved in chemosensitivity and chemoresistance.
Validation of mRNA predictors in independent patient
samples
The true clinical value of gene expression signatures lies in their
ability to predict response in large patient populations. Using
previously developed methods to identify cell lines from the NCI-
60 that represent the extremes of drug sensitivity and the
corresponding updated Affymetrix U133A data, we developed
genomic predictors of TFAC sensitivity [4,6]. This study thus
represents a refined predictive ability due to the use of U133A as
opposed to the U95 data previously used. An independent dataset
of 133 breast cancer tumor samples was used to evaluate the
predictive ability of the U133A T, F, A, and C classifiers. When
the predictive probability values of non-responders and responders
to each individual chemotherapy agent were plotted, the median
probability of sensitivity of the responders was higher than that of
the non-responders (Figure 2) in each case. The probability of 5-
fluorouracil (p=0.02), adriamycin (p=0.01), and cyclophospha-
mide (p=0.02) sensitivity were all significantly different between
responders and non-responders in a Mann-Whitney U test, and
the paclitaxel probability values showed a predictive trend,
although not statistically significant (p=0.07). Importantly, when
the combined TFAC probability was plotted, the probability of
sensitivity in the responders (n=34, Figure 2) was significantly
higher than the probability of sensitivity of the non-responders
(n=99, p=0.002, Mann-Whitney). The sensitivity of the com-
bined predictor was 59%, while the specificity was 63%.
Importantly, the negative predictive value, which is arguably the
most relevant in a clinical scenario, as it should implicate patients
who will not benefit from the treatment in question and should
therefore be considered for other therapeutic options, was found to
be 82%.
Effect of molecular variables on predicted
chemosensitivity patterns
Because molecular variables such as ER, PR, and HER2 status,
as well as Topoisomerase IIA expression, have been shown to have
an effect on chemotherapy sensitivity[17,18], we tested the effect
of these molecular variables on the ability of gene signatures to
accurately identify patients sensitive to TFAC therapy. While the
prediction was significantly more robust in ER and HER negative
patients, PR status had no major effect on TFAC prediction
(Figure 3). When we separated the patients based on ‘basal-like’
(ER, HER, and PR negative) or ‘non basal-like’ status, the
predictive ability of the TFAC combined signature was signifi-
cantly greater in the basal-like patients (Figure 3). It may be
important to note that the basal-like patients also showed a much
higher likelihood of response (48%) as opposed to the non basal-
like patients (19%), as might be expected based on previous
findings reported in the literature [18].
Figure 2. Development and validation of chemotherapeutic response predictors. (a) Strategy for generating the chemotherapeutic
response predictors. (b) Prediction of single-agent chemotherapy response in patient breast samples. Probability values of non-responders (NR) are
shown in red, while probability values of responders (R) are shown in blue. Response was defined as complete pathologic response upon completion
of TFAC neoadjuvant therapy. (c) Combined prediction of sensitivity to the TFAC chemotherapy regimen separated by non-responders (n=99, red)
and responders (n=34, blue).
doi:10.1371/journal.pone.0001908.g002
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IIA inhibitor, and HER2 status has been linked to Topoisomerase
IIA expression[19], we analyzed the effects of HER2 status and
Topoisomerase IIA expression independently on the predictive
ability of the adriamycin sensitivity signature in the 133 patients.
HER2 status seemed to have no major effect on adriamycin
prediction, as both HER2 positive and negative groups of patients
showed a significant difference between the medians of the non-
responders and responders (Figure 4). Topoisomerase IIA
expression, however, had a major effect on adriamycin prediction.
When samples were divided into those with Topoisomerase IIA
expression above and below the median value for each probe, the
predictor for adriamycin sensitivity was significantly more robust
in the samples with high Topoisomerase IIA expression as
compared to low Topoisomerase IIA expression (p values of
0.0021 and 0.0022 versus 0.49 and 0.46, respectively, Figure 4).
Thus, it is likely that stratifying patients first by Topoisomerase IIA
expression before the application of genomic predictors of
chemotherapeutic response may improve the ability of the classifiers
in predicting clinically significant response to adriamycin.
More broadly, this indicates a potential strategy to refine the
predictive ability of gene expression-based signatures of chemo-
sensitivity in breast cancer by first identifying cohorts based on
relevant tumor biology such as ER, HER2 and Topoisomerase
IIA expression.
Patterns of oncogenic pathway activation and alternative
chemotherapeutic options in patients resistant to
standard chemotherapy
The ability to accurately identify patients resistant to standard
chemotherapy also emphasizes the need to dissect cancer biology
further and identify alternative therapeutic strategies for patients
resistant to therapy. To this end, we employed gene signatures
representative of E2F, PI3K, Myc, b-catenin, Src, and Ras
Figure 3. Effect of molecular variables on combined TFAC prediction. Left, TFAC probability values of basal-like (HER2, ER, and PR negative)
and non basal-like patients as separated by non-responders (NR) and responders (R). Right, TFAC probability values of non-responders and
responders separated by ER score less than or greater than 50, PR status, and HER2 status.
doi:10.1371/journal.pone.0001908.g003
Figure 4. Effect of HER2 status and Topoisomerase IIA expression levels on adriamycin prediction. Left, patients were divided
depending on HER2 negative or positive status, and predictive probability values of sensitivity to adriamycin were plotted for non-responders (NR)
and responders (R). Right, patients were divided on the basis of whether their expression of Topoisomerase IIA (obtained using two different probes,
201291_s_at and 201292_at, in the U133A platform) was above or below the median value. Non-responders and responders were separated and their
predictive probability values plotted.
doi:10.1371/journal.pone.0001908.g004
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commonly used cytotoxic agents in breast cancer (docetaxel,
etoposide, vinorelbine and cisplatin), in the cohort of 133 patients.
Interestingly, none of the oncogenic signaling pathways alone
were associated with the likelihood of response to TFAC therapy
(Figure S2). While the knowledge gained from investigating
individual pathways is sometimes critical in elucidating clinically
relevant biology, breast cancer represents a very heterogeneous
disease, the complexity of which may only be dissected by
evaluating the oncogenic cooperation that exists between different
signaling pathways. An approach to evaluating patterns of
oncogenic cooperation between pathways is to use clustering
strategies to demonstrate meaningful interactions between biolog-
ically relevant mechanisms. As shown in Figure 5, unsupervised
hierarchical clustering of the oncogenic pathways E2F, PI3K,
Myc, b-catenin, Src, and Ras in the cohort of 133 patients
demonstrated significant, biologically relevant patterns of pathway
activation. Importantly, analysis comparing the percent of
responders in each cluster showed that two clusters had
significantly higher or lower responder percentages (Figure 5).
Whereas the entire population of patients was comprised of 25%
responders, Cluster 3 had a much higher percentage of responders
at 54%, and Cluster 4 had a lower population of responders at
only 8%. Clusters 1, 2, and 5 had numbers of responders not
significantly different from the entire population. A t-test between
Clusters 3 and 4 showed that they were significantly different
(p=0.003, Mann-Whitney). In the interest of examining the two
extremes of sensitivity, Clusters 3 and 4 were compared for further
analyses. While Cluster 3, with the higher percentage of
responders, seemed to show predominant activation of the Myc
and Ras pathways, Cluster 4 showed activation of the Myc and
E2F pathways. Therefore, we can hypothesize that E2F activation,
in combination with Myc as opposed to Ras activation, may confer
resistance to TFAC chemotherapy in patients with breast cancer.
Further, to identify alternative chemotherapeutic options in
patients resistant to TFAC therapy (Cluster 4), predictive
probabilities of sensitivity to cisplatin, docetaxel, etoposide, and
vinorelbine (Figure 5), all agents commonly used to treat breast
cancer, were generated using U133A data. Interestingly, the most
distinctive characteristic of Cluster 4 was the high probability of
sensitivity to docetaxel (Figure 5). Importantly, a predictor of
docetaxel sensitivity was also validated (p=0.02, Figure S3) in an
independent dataset of 24 patients treated neoadjuvantly with the
single agent docetaxel[20]. This provided us with the opportunity
to compare a robust predictor of docetaxel sensitivity across the
current dataset of 133 patients that were clustered based on their
oncogenic pathway activation status. When compared to patients
in other clusters, the non-responders in Cluster 4 had a
significantly greater probability of responding to docetaxel
(P,0.001, Figure S4). Furthermore, when the probability of
sensitivity to docetaxel was plotted against E2F activation in non-
responders to chemotherapy, a trend towards a positive correla-
tion was observed (P=0.07, Figure S4). This implies that patients
with an activated E2F pathway that are resistant to TFAC may
benefit from the alternative treatment of docetaxel. Previous
studies[21] showed that head and neck squamous cell carcinoma
samples that were resistant to cisplatin and sensitive to docetaxel
(similar to our Cluster 4 tumor samples) showed decreased E2F
activation after treatment with docetaxel, which further supports
the argument that the subset of patients in Cluster 4 may benefit
from alternative treatment with docetaxel. The finding of the
relationship between E2F and docetaxel is interesting biologically
and emphasizes the importance of a validated predictor of
docetaxel sensitivity in patients with early stage breast cancer.
To this extent, we have employed independent data from Chang J
et al [20], a study involving the neoadjuvant use of single agent
docetaxel in patients with breast cancer. As shown in Figure S3, a
U133A predictor of docetaxel (Table S3) accurately separates
responders from non-responders (P=0.02, sensitivity: 90%,
specificity: 57%, positive predictive value: 60%, negative predic-
tive value: 89%, Figure S3).
It is important to emphasize that the results shown here
represent an example of the complexity involved in defining
phenotype of chemosensitive or chemoresistant disease. Knowl-
edge of clinico-pathologic variables likely to affect an individual
patient’s response to a particular drug or regimen will only lead to
Figure 5. Patterns of predicted oncogenic pathway activation and alternative chemotherapeutic options in human breast cancer
tumors. Above, hierarchical clustering of a collection of breast tumors (n=133) according to patterns of oncogenic pathway activation. Below,
predictions of sensitivity to other commonly used chemotherapeutic agents in breast tumors. Predictions were plotted as heatmaps in which a high
probability of sensitivity (or response) is indicated by red, and low probability (or resistance) is indicated in blue. The percentage of responders in
each cluster is reported.
doi:10.1371/journal.pone.0001908.g005
Chemotherapeutic Response
PLoS ONE | www.plosone.org 5 April 2008 | Volume 3 | Issue 4 | e1908the application of gene signatures in a more effective and refined
matter.
Discussion
The selection of the right chemotherapeutic agent for individual
cancer patients remains a challenge. Chemotherapy-associated
morbidity is a major concern, and strategies to limit therapies used
to those that are most likely to be effective have the potential to
change the current paradigm of cancer treatment. The results we
present here provide further evidence that the use of gene
expression data to predict chemotherapy response and oncogenic
pathway activation may assist in selecting therapeutics on a
patient-by-patient basis. While the cell lines used and methods
described are identical to previously validated signatures of
sensitivity, we believe that the development of robust U133A-
platform gene expression signatures of chemosensitivity may be a
very useful tool in further validation strategies and eventually in
guiding patient treatment. Importantly, the paclitaxel, 5-fluoro-
uracil, adriamycin, and cyclophosphamide signatures developed
showed clinically relevant predictive ability in a population of
human breast tumor samples obtained from patients treated
neoadjuvantly with TFAC therapy.
Beyond the development of U133A mRNA signatures for
chemosensitivity, we also present data to suggest that microRNA
expression may be useful in further dissecting the phenomenon of
chemotherapy resistance and in predicting patterns of sensitivity.
This finding is not very surprising, given the fact that microRNAs
can function as either tumor suppressors or as oncogenes, and that
altered microRNA levels are found in various human cancers
[22,23]. Notably, although preliminary, these profiles are the first
to use microRNA data to constitute signatures of chemosensitivity
and resistance. Thus, pending further validation, our results
present preliminary data supporting the hypothesis that micro-
RNA signatures may be used to complement mRNA gene
expression signatures of chemosensitivity.
While the chemotherapy sensitivity signatures described are
useful for predicting which patients will respond to a specific
regimen (TFAC), used alone they do not address the important
issue of alternative therapeutic options for patients who would not
respond to TFAC. Here, we use TFAC as a representative
example of the bigger challenge in oncology with respect to
chemotherapy, the issue of viable options for non-responders to
traditional chemotherapeutic regimens. For this reason, we used
signatures of oncogenic pathway activation[24] as well as
signatures for other commonly used chemotherapy agents in
breast cancer (cisplatin, docetaxel, etoposide, and vinca alkaloids)
to identify potentially activated pathways that might be future
targets for therapy, while also suggesting alternative chemother-
apeutic options. Our data suggest that, in the case of Cluster 4
(which had the lowest percentage of responders) the activated E2F
pathway may be driving chemoresistance, and alternative
treatment with a regimen including docetaxel may have resulted
in an increased number of responders. Importantly, the oncogenic
pathway activation signatures employed were unable alone to
predict responder status of patients, but combined with alternative
chemotherapeutic signatures, they suggest a cohort of patients to
that may benefit from alternative treatment. While our body of
data represents a total of 157 patients, additional studies will be
needed to confirm the trends observed, especially the benefit of
docetaxel treatment in E2F-activated breast cancer cell lines
resistant to other commonly used agents.
In conclusion, the reported chemotherapy sensitivity signatures
can be used effectively in the prediction of response, while other
predictors of oncogenic pathway activation [24] and even tumor
microenvironment should add information that further improves
our understanding of cancer biology while also leading to
alternative therapeutics for predicted non-responders. Important-
ly, relevant molecular or pathologic information may aid our
understanding of chemotherapy resistance and sensitivity in breast
cancer. It is likely that the most optimal approach to prediction of
response to cytotoxic therapy will involve a combination of gene
expression data, microRNA profiles, and molecular variables such
as ER, HER2, and PR status. The goal is to develop a strategy to
determine a personalized treatment approach to breast cancer, so
that each individual patient will have a better chance of a
favorable outcome by matching specific treatment options to their
molecular profiles.
Methods
Development of mRNA and microRNA signatures
The NCI-60 cell lines that were most resistant or sensitive to
each chemotherapy agent were identified as previously de-
scribed[4], and the Affymetrix HG-U133A based NCI-60 cell
line expression data was obtained from the National Institute of
Health (courtesy John Weinstein). Mas5 expression values were
log2 transformed, and class labels (zero or one) were assigned to
sensitive and resistant cell lines. The predictors were optimized for
performance by applying multiple t-tests with a cut-off probability
value of 0.01 using statistical package R[25] (version 2.5.1). Using
methods previously described[4,24], top gene probe identifiers
that best separate sensitive from resistant cell lines were identified.
Leave-one-out cross-validation, in which each cell line is removed
from the signature one-by-one and its predictive probability value
generated using the remaining cell lines, was used to assess the
accurate and robust nature of each individual predictor. As a
proof-of-concept approach to combining probabilities, the TFAC
predictor was generated by taking the mean of the mean-centered
probability values generated by the four individual chemotherapy
sensitivity signatures.
The same NCI-60 cell lines selected for the Affymetrix HG-
U133A-based mRNA signatures were used to develop microRNA
signatures of chemotherapy sensitivity and resistance. MicroRNA
pin-spotted expression data was downloaded from the Cell Miner
database in .gpr format. Using GeneSpring (Agilent), the signal
intensity of each spot was calculated by subtracting local
background (based on the median intensity of the area
surrounding each spot) from the median signal. As a means of
nonspecific filtering, raw values used were limited to those between
8 and 65. Signal intensities were log2 transformed and duplicate
spots were averaged. Quantile normalization was performed
across the 3 microarray batches, all values ,5 were replaced
with the median of such values, and the value for each control cell
line was set to the mean of its five replicates. All control and mouse
probes were removed, and only the resulting 273 human
microRNA probes were used in remaining analyses. Bayesian
binary regression performed in MatLab identified the top gene
probe identifiers used in separating resistant from sensitive cell
lines, and those probes are reported in Table S2.
Patients and Samples
A validation set of 133 human breast cancer samples was
obtained from the MD Anderson Cancer Center website (http://
bioinformatics.mdanderson.org/pubdata.html). This dataset was
selected due to its clinically annotated data (Affymetrix Human
Genome U133A) for patients treated with neoadjuvant chemo-
therapy, an ideal setting to evaluate the efficacy of gene
Chemotherapeutic Response
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with 24 weeks of sequential paclitaxel and fluorouracil-adriamy-
cin-cyclophosphamide neoadjuvant chemotherapy, except two
patients who were treated with either only paclitaxel or a
combination of paclitaxel, 5-fluorouracil, epirubicin, and cyclo-
phosphamide[26]. The clinical data designated patients as either
non-responders (n=99) or responders (n=34) on the basis of
pathologic complete response; in other words, responders showed
no signs of residual invasive cancer in the breast or lymph nodes at
the time of surgery. HER2 status, ER status (based on ER score),
and PR status were obtained from the clinical data provided on
the M.D. Anderson website and used in the analysis of the effect of
molecular variables on chemotherapy sensitivity prediction. ‘Basal-
like’ patients were defined as patients with negative ER, HER2,
and PR status. Topoisomerase IIA expression was obtained from
the log2-transformed expression data from two representative
probes, 201281_s_at and 201292_at, and divided into values
above and below the median. For the docetaxel validation, an
independent dataset of 24 samples treated neoadjuvantly with
docetaxel was used[20].
Application of oncogenic pathway activation and
alternative chemotherapeutic agent signatures
Oncogenic pathway signatures described previously[24] were
used to create predictive probability values for activation of the b-
catenin, E2F, Myc, PI3K, Ras, and Src pathways. The pathway
signatures, combined with the validation set of breast tumor
samples, were standardized using MatLab (version 7.1). Bayesian
probit binary regression analysis was then performed on the
datasets, and the resultant probability values generated. Unsuper-
vised hierarchical clustering was performed using complete linkage
clustering with Pearson correlation coefficient in the Gene
Pattern[27](Hierarchical Clustering module, version 3.0) software
package, and a heatmap was then generated. Clusters were
assigned by visualization of the corresponding dendrogram, and
the percent of responders in each cluster were calculated.
Genomic signatures for docetaxel, etoposide, cisplatin, and a
vinca alkaloid (a surrogate for vinorelbine) were applied to the
breast tumor validation set to identify alternative chemotherapeu-
tic options for non-responders to TFAC. The signatures for
docetaxel and etoposide were developed as described above for the
individual TFAC predictors. Briefly, cell lines selected from the
NCI-60 for the Affymetrix HG-U95 based Av2 predictors[4] were
used in the HG-U133A-based docetaxel and etoposide predictors,
multiple t-tests were applied on the dataset using statistical
package R (version 2.5.1), and the binary regression parameters
were adjusted to achieve optimal cross-validation accuracy. The
signatures for cisplatin and vinca alkaloid were developed using a
set of 30 human cancer cell lines[28]. Resultant predictive
probability values were displayed as a heatmap using Heatmap-
Viewer module of the GenePattern software based on patient
sample order obtained earlier from the unsupervised hierarchical
clustering of the oncogenic pathway activation probability values.
Clusters previously defined based on the patterns of oncogenic
pathway activation were analyzed to assess whether alternative
chemotherapeutic options were likely to be effective for specific
patient clusters predicted to be predominantly resistant to the
original chemotherapy agent.
Supporting Information
Figure S1 mRNA gene signatures of sensitivity to paclitaxel, 5-
fluorouracil, adriamycin, and cyclophosphamide. Heatmaps, with
gene number on the horizontal axis and sample number on the
vertical axis, are shown above. Below, leave-one-out cross-
validation of samples selected to represent resistance (blue) and
sensitivity (red) to each chemotherapeutic agent.
Found at: doi:10.1371/journal.pone.0001908.s001 (4.86 MB TIF)
Figure S2 Individual oncogenic pathway signatures as applied to
the cohort (n=133) of breast cancer patients. Non-responders and
responders were separated and their predictive probability values
plotted.
Found at: doi:10.1371/journal.pone.0001908.s002 (2.05 MB TIF)
Figure S3 Validation of a U133A predictor of docetaxel
sensitivity in an independent dataset of 24 samples from patients
treated neoadjuvantly with single agent docetaxel
Found at: doi:10.1371/journal.pone.0001908.s003 (1.21 MB TIF)
Figure S4 Docetaxel sensitivity and E2F activation in TFAC
non-responders. The predicted probability of sensitivity to
docetaxel of the TFAC non-responders as divided by individual
clusters (Panel A) and Cluster 4 compared with the other clusters
(Panel B). Panel C shows a linear regression analysis of the
probability of sensitivity to docetaxel plotted against the E2F
oncogenic pathway activation.
Found at: doi:10.1371/journal.pone.0001908.s004 (2.37 MB TIF)
Table S1 Ontology of genes used in the TFAC chemotherapy
sensitivity signatures.
Found at: doi:10.1371/journal.pone.0001908.s005 (0.57 MB
DOC)
Table S2 Ontology of miRNA genes used in chemotherapy
sensitivity signatures.
Found at: doi:10.1371/journal.pone.0001908.s006 (0.07 MB
DOC)
Table S3 Ontology of genes used in the docetaxel sensitivity
signature.
Found at: doi:10.1371/journal.pone.0001908.s007 (0.21 MB
DOC)
Acknowledgments
The authors thank the research support from the Jimmy V foundation and
the Emilene Brown Cancer Research Fund.
Author Contributions
Conceived and designed the experiments: JN JO AP KM KS. Performed
the experiments: CA KS. Analyzed the data: SM HD AP CA KS KW WB.
Contributed reagents/materials/analysis tools: SM HD JN JO AP CA WB.
Wrote the paper: JN AP KG KM KS KW RR AA. Other: Designed the
study: AP.
References
1. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, et al. (2001)
Chemosensitivitypredictionbytranscriptionalprofiling.ProcNatlAcadSciUSA
98: 10787–19792.
2. Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, et al. (2006) Clinical
Cancer Advances 2005: major research advances in cancer treatment,
prevention, and screening–a report from the American Society of Clinical
Oncology. J Clin Oncol 24: 190–205.
3. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, et al. (2001)
Twenty-two years of phase III trials for patients with advanced non-small-cell
lung cancer: sobering results. J Clin Oncol 19: 1734–1742.
4. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, et al. (2006) Genomic
signatures to guide the use of chemotherapeutics. Nat Med 12: 1294–1300.
5. Nevins JR, Potti A (2007) Mining gene expression profiles: expression signatures
as cancer phenotypes. Nat Rev Genet 8: 601–609.
Chemotherapeutic Response
PLoS ONE | www.plosone.org 7 April 2008 | Volume 3 | Issue 4 | e19086. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, et al. (2007)
Validation of gene signatures that predict the response of breast cancer to
neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01
clinical trial. Lancet Oncol.
7. Hsu DS, Balakumaran BS, Acharya CR, Vlahovic V, Walters KS, et al. (2007)
Pharmacogenomic strategies provide a rational approach to the treatment of
cisplatin-resistant patients with advanced cancer. J Clin Oncol 25: 4350–4357.
8. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, et al.
(2007) Transactivation of miR-34a by p53 broadly influences gene expression
and promotes apoptosis. Mol Cell 26: 745–752.
9. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, et al. (2007) p53-
mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol
17: 1298–1307.
10. He L, He X, Lim LP, de Stanchina E, Xuan Z, et al. (2007) A microRNA
component of the p53 tumour suppressor network. Nature 447: 1130–1134.
11. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, et al. (2007)
Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.
Mol Cell 26: 731–743.
12. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, et al. (2007)
Differential regulation of microRNAs by p53 revealed by massively parallel
sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell
Cycle 6: 1586–1593.
13. Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to
antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin
Oncol 17: 1061–1070.
14. Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M (2007) Synergistic action
of the microRNA-17 polycistron and Myc in aggressive cancer development.
Cancer Sci 98: 1482–1490.
15. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, et al. (2007) Let-7 prevents
early cancer progression by suppressing expression of the embryonic gene
HMGA2. Cell Cycle 6: 2585–2590.
16. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, et al. (2006)
Involvement of human micro-RNA in growth and response to chemotherapy in
human cholangiocarcinoma cell lines. Gastroenterology 130: 2113–2129.
17. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, et al. (2007) HER2
and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:
1496–1506.
18. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, et al. (2005)
Breast cancer molecular subtypes respond differently to preoperative chemo-
therapy. Clin Cancer Res 11: 5678–5685.
19. Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V (2007) The
17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to
the biology of solid tumours. Cancer Treat Rev 33: 64–77.
20. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, et al.
(2003) Gene expression profiling for the prediction of therapeutic response to
docetaxel in patients with breast cancer. Lancet 362: 362–369.
21. Yoo GH, Piechocki MP, Ensley JF, Nguyen T, Oliver J, et al. (2002) Docetaxel
induced gene expression patterns in head and neck squamous cell carcinoma
using cDNA microarray and PowerBlot. Clin Cancer Res 8: 3910–3921.
22. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent
deletions and down-regulation of micro- RNA genes miR15 and miR16 at
13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:
15524–15529.
23. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. (2006) A microRNA
expression signature of human solid tumors defines cancer gene targets. Proc
Natl Acad Sci U S A 103: 2257–2261.
24. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway
signatures in human cancers as a guide to targeted therapies. Nature 439:
353–357.
25. Ihaka RaG, RE (1996) R: A Language for Data Analysis and Graphics. Journal
of Computational and Graphical Statistics 5: 299–314.
26. Pusztai L, Anderson K, Hess KR (2007) Pharmacogenomic Predictor Discovery
in Phase II Clinical Trials for Breast Cancer. Clin Cancer Res 13: 6080–6086.
27. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0.
Nat Genet 38: 500–501.
28. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, et al. (2006) Gene
expression profiling of 30 cancer cell lines predicts resistance towards 11
anticancer drugs at clinically achieved concentrations. Int J Cancer 118:
1699–1712.
Chemotherapeutic Response
PLoS ONE | www.plosone.org 8 April 2008 | Volume 3 | Issue 4 | e1908